Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate

Journal of Neural Transmission

Volumn 110, Issue 8, 2003, Pages 871-883

  Shimazu, S ^a   Takahata, K ^a   Tamashiro, A ^a   Yoneda, F ^a   Iida, Y ^b   Saji, H ^b  

^a Fujimoto Pharmaceutical Corporation   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Diethyldithiocarbamate (DDC); L DOPA; Parkinson's disease; Selegiline

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DIETHYLDITHIOCARBAMIC ACID; DOPAMINE RECEPTOR; HOMOVANILLIC ACID; LEVODOPA; SELEGILINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; MOTOR PERFORMANCE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; STRIATE CORTEX;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; DITIOCARB; DOPAMINE; DRUG SYNERGISM; HOMOVANILLIC ACID; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; REACTION TIME; RECOVERY OF FUNCTION; SELEGILINE; SEROTONIN;

EID: 0041402637     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0002-1     Document Type: Article

References (38)

1. Arai N, Misugi K, Goshima Y, Misu Y (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 515: 57-63
2. Benloucif S, Galloway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200: 1-8
3. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson's disease. Bioessays 24: 308-318
4. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64: 113-127
5. 4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rats. Neuropharmacology 34: 269-279
6. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546-4550
7. Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology (Berl) 102: 295-300
8. Corsini GU, Pintus S, Chiueh CC, Weiss JF, Kopin IJ (1985) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol 119: 127-128
9. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249-254
10. 1A dopamine receptors. Proc Natl Acad Sci USA 91: 12564-12568
11. Fredriksson A, Archer T (1995) Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. J Neural Transm [Gen Sect] 102: 19-34
12. Hallman H, Lange J, Olson L, Strömberg I, Jonsson G (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 44: 117-127
13. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469
14. Irwin I, Wu EY, DeLanney LE, Trevor A, Langston JW (1987) The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur J Pharmacol 141: 209-217
15. Kopin IJ, Markey SP (1988) MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 11: 81-96
16. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
17. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73: 45-48
18. Miller DB, Reinhard JF Jr, Daniels AJ, O'Callaghan JP (1991) Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J Neurochem 57: 541-549
19. Mitsumoto Y, Watanabe A, Mori A, Koga N (1998) Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Commun 248: 660-663
20. +) against mitochondria of mouse brain. J Neurol Sci 86: 97-110
21. Mori S, Fujitake J, Kuno S, Sano Y (1988) Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Neurosci Lett 90: 57-62
22. Nishi K, Kondo T, Narabayashi H (1989) Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice. Brain Res 489: 157-162
23. B inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology 32: 473-477
24. Nyitrai G, Kekesi KA, Dobolyi K, Pungor K, Juhasz G (1997) Single low dose of MPTP decreases extracellular levels of noradrenaline and monoamine metabolites in the ventrobasal thalamus of the rats. Neurobiology 5: 249-261
25. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50: 435-441
26. Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y (1987) MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur Neurol 26 [Suppl 1]: 16-23
27. Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology 119: 466-473
28. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL (1998) Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245: 151-154
29. Sundström E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res 528: 181-188
30. Szczypka MS, Rainey MA, Kim DS, Alaynick WA, Marck BT, Matsumoto AM, Palmiter RD (1999) Feeding behavior in dopamine-deficient mice. Proc Natl Acad Sci USA 96: 12138-12143
31. Takahata K, Shimazu S, Yoneda F, Ogawa M, Iida Y, Saji H (2003) Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. J Neural Transm 110 (in press)
32. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10: 631-634
33. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371
34. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191-1206
35. Vaglini F, Fascetti F, Fornai F, Maggio R, Corsini GU (1994) (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res 668: 194-203
36. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM (1999) Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 156: 62-70
37. Zuddas A, Vaglini F, Fornai F, Corsini GU (1992) Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehyde or diethyldithiocarbamate. Neurochem Int 20 [Suppl]: 287S-293S
38. + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Exp Neurol 127: 54-61